BiotechTube

Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection

Phase 2Active
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity

Conditions

Obesity

Trial Timeline

Aug 22, 2024 → Feb 28, 2027

NCT ID
NCT06577090

About Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection

Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection is a phase 2 stage product being developed by Skye Bioscience for Obesity. The current trial status is active. This product is registered under clinical trial identifier NCT06577090. Target conditions include Obesity.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06577090Phase 2Active

Competing Products

20 competing products in Obesity

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
52
MK0557MerckPhase 3
77
AMG 786AmgenPhase 1
32
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
52
TirzepatideEli LillyPhase 2
52
exenatide + PlaceboEli LillyApproved
85
BrenipatideEli LillyPhase 1
33
Orforglipron + PlaceboEli LillyPhase 3
77
TERN-601Terns PharmaceuticalsPhase 2
49
MBX 4291 + PlaceboMBX BiosciencesPhase 1
28
PG-102Rani TherapeuticsPhase 1
25
Orforglipron + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide + PlaceboEli LillyPhase 1
33
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
52
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
33
TirzepatideEli LillyApproved
85
Adenosine + RegadenosonAstellas PharmaPre-clinical
23
Micafungin + MicafunginAstellas PharmaApproved
85
MicafunginAstellas PharmaApproved
85

Other Products from Skye Bioscience

SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboPhase 2
44